Tissue pharmacokinetics of daptomycin measured by in vivo microdialysis in patients with diabetic foot infection

PD Dr. med. K-H. Konz0 个研究点开始时间: 2008年10月15日最近更新: 2012年3月19日

试验速览

暂无简介。

•1. Written informed consent to participate in the study.
•2. Male or female patient of 18 years of age or older.
•3. Patient suffers from documented diabetes and soft tissue infection of the lower limb.
•4. Requires intravenous broad-spectrum anti-microbial therapy
•5. CRP higher than 5 mg/dl at baseline
•6. Patient has no relevant renal dysfunction indicated by a creatinine clearance =40 ml/min as determined by the Cockcroft-Gault equation using actual body weight (Appendix 4).
•7. Negative urine pregnancy test in females of childbearing potential
•8. Patient is willing to participate in the study, follow protocol study treatment regimen, and comply with all planned assessments.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Treatment with the study drug within the past three weeks prior to study enrolment.
•2. Site of infection other than infection of the lower limb
•3. History of hypersensitivity to the study drug
•4. Patients submitted to the hospital with known pathogens resistant to study drug.
•5. Patient with a neutrophils count <1000/m3.
•6. Use of any other investigational therapy at the time of enrolment, or within 30 days or 5 half-lives before inclusion into, whichever is longer.
•7. Patients unable or unwilling to adhere to the study-designated procedures and restrictions.
•8. Unable to understand the nature, purpose and extent of the study
•9. Nursing women

发起方

PD Dr. med. K-H. Konz